核心观点 - Travere Therapeutics 2026年9月止季度营收2.2456亿美元，同比增长36.2%，超出Zacks共识预期1.9252亿美元，意外幅度+16.64% [1] - 同季度每股收益为-0.55美元，上年同期为0.28美元，共识预期为-0.25美元，EPS意外幅度为-120% [1] - 关键经营指标对理解公司底层表现至关重要，将其与上年同期数据及分析师预期对比有助于预测股价表现 [2] - 公司股价过去一个月回报率为-11.5%，同期Zacks标普500综合指数变动为-0.9% [3] 营收分项表现 - 总净产品销售额为2.202亿美元，五名分析师平均预期为1.8628亿美元，同比增长94.6% [4] - FILSPARI净产品销售额为2.0019亿美元，五名分析师平均预期为1.6505亿美元，同比增长120.2% [4] - Tiopronin产品净产品销售额为2000万美元，五名分析师平均预期为1994万美元，同比下降10.1% [4] - 许可与合作协议收入为437万美元，五名分析师平均预期为528万美元，同比下降91.6% [4]

Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.Total U.S. net product sales reached $220.2 million in the third quarter, led by $200.2 million in FILSPARI sales. FILSPARI sales increased approximately 120% from a year earlier, reflecting continued growth in immunoglobulin A nephropathy (IgAN) and the first significant reven ...

Travere Therapeutics (NasdaqGM:TVTX) Q3 2026 Earnings call November 02, 2026 04:30 PM ET Company ParticipantsEric Dube - President and CEOPeter Heerma - Chief Commercial OfficerJula Inrig - Head of R&D and Chief Medical OfficerChris Cline - CFOLaura Chico - Managing Director, Co-Head of Healthcare ResearchJoe Schwartz - Managing DirectorGavin Clark-Gartner - Managing DirectorPrakhar Agrawal - Managing DirectorSadia Rahman - Vice PresidentAlex Thompson - Research Managing DirectorVamil Divan - Managing Direc ...

Travere Therapeutics (NasdaqGM:TVTX) Q3 2026 Earnings call November 02, 2026 04:30 PM ET Speaker0Good afternoon, and welcome to the Travere Therapeutics Third Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Ryan Hayes, Investor Relations Analyst. Please go ahead, Ryan.Speaker1Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' Third Quarter 2026 Financial Results and Corporate Update Call. Th ...